Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation
Insulin and insulin growth factor type 1 (IGF-1) and their receptors are closely related molecules, but both factors bind to the receptor of the other one with a weak affinity. No study has presently documented a role of insulin as a myeloma growth factor (MGF) for human multiple myeloma cells (MMCs...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 September 2010
|
| In: |
Leukemia
Year: 2010, Volume: 24, Issue: 11, Pages: 1940-1950 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2010.192 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/leu.2010.192 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/leu2010192 
|
| Author Notes: | A.C. Sprynski, D. Hose, A. Kassambara, L. Vincent, M. Jourdan, J.F. Rossi, H. Goldschmidt and B. Klein |
| Summary: | Insulin and insulin growth factor type 1 (IGF-1) and their receptors are closely related molecules, but both factors bind to the receptor of the other one with a weak affinity. No study has presently documented a role of insulin as a myeloma growth factor (MGF) for human multiple myeloma cells (MMCs), whereas many studies have concluded that IGF-1 is a major MGF. IGF-1 receptor (IGF-1R) is aberrantly expressed by MMCs in association with a poor prognosis. In this study we show that insulin receptor (INSR) is increased throughout normal plasma cell differentiation. INSR gene is also expressed by MMCs of 203/206 newly diagnosed patients. Insulin is an MGF as potent as IGF-1 at physiological concentrations and requires the presence of insulin/IGF-1 hybrid receptors, stimulating INSR+IGF-1R+ MMCs, unlike INSR+IGF-1R− or INSR−IGF-1R− MMCs. Immunoprecipitation experiments indicate that INSR is linked with IGF-1R in MMCs and that insulin induces both IGF-1R and INSR phosphorylations and vice versa. In conclusion, we demonstrate for the first time that insulin is an MGF as potent as IGF-1 at physiological concentrations and its activity necessitates insulin/IGF-1 hybrid receptor activation. Further therapeutic strategies targeting the IGF/IGF-1R pathway have to take into account neutralizing the IGF-1R-mediated insulin MGF activity. |
|---|---|
| Item Description: | Gesehen am 05.10.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2010.192 |